Eyestem Reported Phase 2 Results for Macular Degeneration
The therapy aims to restore vision in patients with dry age-related macular degeneration by targeting retinal cells.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you trust that new clinical trial results for macular degeneration signal genuine medical progress?
Eyestem Research presented interim Phase 2 clinical trial results for Eyecyte-RPE, a treatment designed for dry age-related macular degeneration. The study, which remains in the research stage, evaluates the efficacy of the therapy on patients experiencing geographic atrophy.
Why it matters
The study aims to provide a viable treatment for geographic atrophy, a leading cause of vision loss in dry macular degeneration. Researchers are working to validate the safety and functional impact of the RPE cell therapy approach.
Twelve subjects across two phases demonstrated an average 13.8-letter improvement at six months, while four subjects maintained a 15.3-letter gain at 18 months. The study utilized a patent-pending surgical technique executed by seven surgeons.
The players
Eyestem Research
A biotechnology firm developing cell therapies specifically for the treatment of degenerative retinal diseases.
The details
The trial evaluates Eyecyte-RPE, an investigational therapy that likely involves the delivery of retinal pigment epithelium cells, which are cells essential for nourishing and maintaining the light-sensing photoreceptor cells in the eye. Surgeons delivered the treatment using a patent-pending technique designed for precision in cases of geographic atrophy, a condition characterized by the gradual deterioration of the macula, the central part of the retina. This research-stage procedure requires high-skill administration to ensure the proper placement of the therapeutic cells.
Timeline
October 5, 2026: Eyestem presented interim trial results at the EURetina conference in Vienna.
Early 2027: Eyestem expects to file a US Investigational New Drug application.
The Tech Race
This development marks a competitive milestone in the effort to replace damaged retinal cells through advanced cell therapy. Eyestem is now positioning its RPE technology against emerging restorative methods currently under investigation for dry age-related macular degeneration.
The therapy is currently confined to clinical research and is not available for public medical treatment. Patients should monitor the company's progress toward its planned US Investigational New Drug application in early 2027, which is a required step for initiating wider clinical testing.
The takeaway
The study demonstrates measurable visual acuity improvements in a small cohort, signaling a move toward more rigorous regulatory review. Watch for the company's 2027 US IND filing as a key indicator of its ability to scale the therapy to larger patient populations.
Further reading
For broader trends in cell-based vision repair, explore the latest research in /Biotech.
Live Poll
Do you trust that new clinical trial results for macular degeneration signal genuine medical progress?
